Nádory krčního úseku jícnu jsou vzácným onemocněním, které se standardně léčí samostatnou (definitivní) chemoradioterapií bez chirurgického výkonu. Chemoradioterapie je provázena několika kontroverzemi, z nichž hlavní je nejistota v účinné dávce a přínosu dávkové eskalace. Běžná aplikovaná normofrakcionovaná dávka je přes 60 Gy. Příznivá dávková distribuce predikuje benefit protonové radioterapie (PRT). V PTC Praha lze výsledky PRT hodnotit u 29 nemocných, kteří byli ozařováni do c. d. 70 GyE technikou „pencil beam scanning“ IMPT s konkomitantní chemoterapií carboplatina + paclitaxel. U 18, resp. 7 nemocných byla dosažena kompletní, resp. parciální regrese, response rate je 86,3 %. Medián sledování je 14 měsíců (2,6–66,0). Medián přežívání je 13,7 měs., 2leté přežívání 45 %. Medián doby do relapsu/progrese je 28,7 měs., 2leté přežívání bez relapsu je 52 %. V době analýzy přežívá 13 nemocných, 12 z nich v kompletní regresi onemocnění. Akutní toxicita nepřesahuje stupeň 2 kromě kožní (st. 3 u 22,6 %). Chronická toxicita nepřesahuje st. 2 kromě 2 případů tracheoezofageální píštěle v místě primárního postižení u onemocnění stadia T4. PRT v mírně eskalované dávce s konkomitantní chemoterapií dosáhla vysokou protinádorovou účinnost, naproti tomu parametry přežívání jsou zřejmě vlivem velkého podílu primárně lokoregionálně pokročilých onemocnění méně příznivé. Přesto určitý podíl nemocných dlouhodobě přežívá s kompletní regresí onemocnění. Obligátní výskyt lymfopenie a řada recentních poznatků v protinádorové imunologii vyžaduje rozvahu nad dosavadním konceptem určování objemu a frakcionace.

Cancer of cervical esophagus belongs to rare diseases. Its standard treatment includes definitive chemoradiotherapy without subsequent surgery. There are several controversies concerning chemoradiotherapy, the most substantial of them being uncertain effective dose and uncertain benefit of dose escalation. The doses exceeding 60 Gy in 30 fractions are frequently administered. A benefit of proton radiotherapy (PRT) is predicted by favorable dose distribution. The results of PRT administered in PTC Prague have been assessed in 29 patients who have been irradiated up to 70 Gy (equivalent) in 35 fractions using pencil beam scanning technique with concomitant weekly chemotherapy carboplatinum plus paclitaxel. A complete and partial regression has been achieved in 18 and 7 patients respectively, response rate 86,3%. The median follow up time is 14 months (2,6-66,0). Median survival time is 13,7 months, 2-year survival 45%, median time to relapse/progression 28,7 months and 2-year relapse free survival 52%. 13 patients survive at the time of analysis, 12 in complete regression. The acute toxicity does not exceed the grade 2, except radiation dermatitis (22,6% grade 3). The late toxicity does not exceed grade 2, except tracheoesophageal fistulation in 2 patients with primary T4 lesion. The PRT in moderately escalated dose with concomitant chemotherapy achieved a high antitumor efficacy opposed to less favorable survival results, presumably originating of substantial number of locoregionally advanced diseases. Still a durable complete regression long time survival is being observed in a certain share of patients. A lymphopenia is obligatory and in a scope of recent observations in antitumor immunology it desires a deeper contemplation on target volume and fractionation concept.

• Klíčová slova
• protonová chemoradioterapie,
• MeSH
• chemoradioterapie metody   MeSH
• lidé MeSH
• lymfopenie MeSH
• nádory jícnu * farmakoterapie   radioterapie   MeSH
• protonová terapie * metody   MeSH
• retrospektivní studie MeSH
• Check Tag
• lidé MeSH

BACKGROUND: We retrospectively analyzed the 5-year biochemical disease-free survival (bDFS) and occurrence of late toxicity in prostate cancer patients treated with pencil beam scanning (PBS) proton radiotherapy. METHODOLOGY: In the period from January 2013 to June 2018, 853 patients with prostate cancer were treated with an ultra-hypofractionated schedule (36.25 GyE/five fractions). The mean PSA value was 6.7 (0.7-19.7) μg/L. There were 318 (37.3%), 314 (36.8%), and 221 (25.9%) patients at low (LR), favorable intermediate (F-IR), and unfavorable intermediate risk (U-IR), respectively. Neoadjuvant hormonal therapy was administered to 197 (23.1%) patients, and 7 (0.8%) patients had adjuvant hormonal therapy. The whole group of patients reached median follow-up time at 62.7 months, and their mean age was 64.8 (40.0-85.7) years. The bDFS rates and late toxicity profile were evaluated. RESULTS: Median treatment time was 10 (7-38) days. Estimated 5-year bDFS rates were 96.5%, 93.7%, and 91.2% for low-, favorable intermediate-, and unfavorable intermediate-risk groups, respectively. Cumulative late toxicity (CTCAE v4.0) of G2+ was as follows: gastrointestinal (GI)-G2: 9.1%; G3: 0.5%; genitourinary (GU)-G2: 4.3%, and no G3 toxicity was observed. PSA relapse was observed in 58 (6.8%) patients: 16 local, 22 lymph node, 4 bone recurrences, and 10 combined sites of relapse were detected. Throughout the follow-up period, 40 patients (4.7%) died, though none due to prostate cancer. CONCLUSION: Ultra-hypofractionated proton beam radiotherapy is an effective treatment for low- and favorable intermediate-risk prostate cancer, with long-term bDFS rates comparable to other techniques. It is promising for unfavorable intermediate-risk prostate cancer and has acceptable long-term GI and favorable GU toxicity.

• Publikační typ
• časopisecké články MeSH

BACKGROUND: An indication for selective shunting during carotid endarterectomy (CEA) is based on monitoring during a procedure. Cerebral oximetry (CO) using near-infrared spectroscopy (NIRS) may be a simple technique, but its relevance during CEA, especially with respect to cutoff values indicating shunt implantation, still needs to be elucidated. METHODS: One hundred twenty five patients underwent CEA under local anesthesia (LA) and were monitored clinically throughout the whole procedure. The patients were also monitored using bilateral NIRS probes during surgery. The NIRS values were recorded and evaluated before and after selective cross-clamping, firstly by the external carotid artery (ECA), followed by the internal carotid artery (ICA). The decrease in the ipsilateral CO values, with respect to the indication of shunting, was only analyzed after selective cross-clamping of the ICA. The decision to use an intraluminal shunt was solely based on the neurological status evaluation after ICA cross-clamping. RESULTS: One hundred five patients (85%) were stable throughout the CEA, while 20 patients (15%) clinically deteriorated during surgery. The mean drop in the CO after selective ICA clamping in clinically stable patients was 6%, while in patients with clinical deterioration, the NIRS decreased by 14.5% (p < 0.05). When the cutoff value for selective shunting was set as a 10% decrease of the ipsilateral CO after selective ICA clamping, the sensitivity of the technique was 100% and the specificity 83.0%. CONCLUSIONS: Our study showed that a 10% decrease in the ipsilateral brain tissue oximetry after selective cross-clamping the ICA provides a reliable cutoff value for selective shunting during CEA. Despite the availability of a variety of monitoring tools, the NIRS may be an easy, reliable option, especially in the scenario of acute CEA in general anesthesia.

• MeSH
• arteria carotis externa diagnostické zobrazování   chirurgie   MeSH
• arteria carotis interna diagnostické zobrazování   chirurgie   MeSH
• blízká infračervená spektroskopie MeSH
• chirurgické nástroje * MeSH
• difuzní magnetická rezonance MeSH
• karotická endarterektomie * MeSH
• konstrikce MeSH
• lidé středního věku MeSH
• lidé MeSH
• mozek diagnostické zobrazování   patofyziologie   chirurgie   MeSH
• neurochirurgické výkony * MeSH
• oxymetrie * MeSH
• prospektivní studie MeSH
• ROC křivka MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• pozorovací studie MeSH
• práce podpořená grantem MeSH

Methacrylate hydrogels have been extensively used as bridging scaffolds in experimental spinal cord injury (SCI) research. As synthetic materials, they can be modified, which leads to improved bridging of the lesion. Fibronectin, a glycoprotein of the extracellular matrix produced by reactive astrocytes after SCI, is known to promote cell adhesion. We implanted 3 methacrylate hydrogels: a scaffold based on hydroxypropylmethacrylamid (HPMA), 2-hydroxyethylmethacrylate (HEMA) and a HEMA hydrogel with an attached fibronectin (HEMA-Fn) in an experimental model of acute SCI in rats. The animals underwent functional evaluation once a week and the spinal cords were histologically assessed 3 months after hydrogel implantation. We found that both the HPMA and the HEMA-Fn hydrogel scaffolds lead to partial sensory improvement compared to control animals and animals treated with plain HEMA scaffold. The HPMA scaffold showed an increased connective tissue infiltration compared to plain HEMA hydrogels. There was a tendency towards connective tissue infiltration and higher blood vessel ingrowth in the HEMA-Fn scaffold. HPMA hydrogels showed a significantly increased axonal ingrowth compared to HEMA-Fn and plain HEMA; while there were some neurofilaments in the peripheral as well as the central region of the HEMA-Fn scaffold, no neurofilaments were found in plain HEMA hydrogels. In conclusion, HPMA hydrogel as well as the HEMA-Fn scaffold showed better bridging qualities compared to the plain HEMA hydrogel, which resulted in very limited partial sensory improvement.

• MeSH
• axony fyziologie   MeSH
• biokompatibilní materiály MeSH
• biologické markery MeSH
• exprese genu MeSH
• extracelulární matrix metabolismus   MeSH
• fyziologická neovaskularizace MeSH
• hematoencefalická bariéra metabolismus   MeSH
• hojení ran MeSH
• hydrogely * MeSH
• krysa rodu rattus MeSH
• methakryláty * chemie   MeSH
• modely nemocí na zvířatech MeSH
• pojivová tkáň MeSH
• poranění míchy etiologie   metabolismus   patologie   terapie   MeSH
• regenerace nervu * MeSH
• tkáňové podpůrné struktury MeSH
• zvířata MeSH
• Check Tag
• krysa rodu rattus MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH